J Refract Surg. 2021 May;37(5):351-359. doi: 10.3928/1081597X-20210115-03. Epub 2021 May 1.
To summarize the indications and outcomes of posterior chamber phakic intraocular lens (PIOL) implantation in corneal ectasias including keratoconus, pellucid marginal degeneration (PMD), post-refractive surgery, and post-keratoplasty ectasias.
A review of the literature was conducted using the relevant keywords from various databases up to August 15, 2020. All pertinent studies were reviewed, and the relevant articles were studied in detail for efficacy, stability, predictability, and safety outcomes. In addition, visual quality, corneal biomechanical outcomes, complications, the role of posterior chamber PIOL in combination treatment, and comparison of posterior chamber PIOL with other PIOLs for ectasias were also evaluated.
A total of 30 relevant studies (13 prospective, 13 retrospective, 4 case reports) on the subject were studied and summarized. All studies showed a favorable refractive outcome. Quality of vision remained unaffected and no significant complications were reported in any of the studies.
Posterior chamber PIOLs represent a viable option in the treatment of mild to moderate and stable corneal ectasia in patients with contact lens intolerance who have low irregular astigmatism, a clear central cornea, and good preoperative corrected distance visual acuity. .
总结后房型有晶状体眼人工晶状体(PIOL)植入术治疗角膜扩张症(包括圆锥角膜、边缘性角膜变性、屈光手术后和角膜移植术后扩张)的适应证和疗效。
通过检索各数据库中相关的关键词,对截至 2020 年 8 月 15 日的文献进行回顾。对所有相关研究进行综述,并对相关文章进行详细研究,以评估其疗效、稳定性、可预测性和安全性。此外,还评估了视觉质量、角膜生物力学结果、并发症、后房型 PIOL 在联合治疗中的作用以及后房型 PIOL 与其他 PIOL 治疗扩张症的比较。
共研究和总结了 30 项关于该主题的相关研究(13 项前瞻性,13 项回顾性,4 项病例报告)。所有研究均显示出良好的屈光效果。视力质量保持不变,任何研究均未报告明显并发症。
在后房型有晶状体眼人工晶状体治疗轻至中度和稳定的角膜扩张症方面,对于有接触镜不耐受、低度不规则散光、透明中央角膜和良好术前矫正远视力的患者,是一种可行的选择。